NO332992B1 - Disintegreringsmidler for torrpulverinhalatorer og inhalator - Google Patents
Disintegreringsmidler for torrpulverinhalatorer og inhalatorInfo
- Publication number
- NO332992B1 NO332992B1 NO20035654A NO20035654A NO332992B1 NO 332992 B1 NO332992 B1 NO 332992B1 NO 20035654 A NO20035654 A NO 20035654A NO 20035654 A NO20035654 A NO 20035654A NO 332992 B1 NO332992 B1 NO 332992B1
- Authority
- NO
- Norway
- Prior art keywords
- chamber
- particles
- air
- carrier
- channel
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 150
- 239000007884 disintegrant Substances 0.000 title claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 260
- 239000000203 mixture Substances 0.000 claims abstract description 109
- 238000009472 formulation Methods 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims description 105
- 239000003814 drug Substances 0.000 claims description 105
- 239000010419 fine particle Substances 0.000 claims description 70
- 239000008188 pellet Substances 0.000 claims description 64
- 230000003434 inspiratory effect Effects 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 32
- 230000008021 deposition Effects 0.000 claims description 24
- 230000033001 locomotion Effects 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 16
- 238000009826 distribution Methods 0.000 claims description 15
- 239000000443 aerosol Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000036961 partial effect Effects 0.000 claims description 13
- 230000014759 maintenance of location Effects 0.000 claims description 12
- 230000001133 acceleration Effects 0.000 claims description 10
- 229940112141 dry powder inhaler Drugs 0.000 claims description 10
- 230000000717 retained effect Effects 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 7
- 230000004888 barrier function Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 4
- 239000012798 spherical particle Substances 0.000 claims description 3
- 239000003570 air Substances 0.000 description 164
- 239000000853 adhesive Substances 0.000 description 48
- 230000001070 adhesive effect Effects 0.000 description 48
- 239000013078 crystal Substances 0.000 description 43
- 238000000151 deposition Methods 0.000 description 24
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 22
- 229960001375 lactose Drugs 0.000 description 22
- 239000008101 lactose Substances 0.000 description 22
- 238000002156 mixing Methods 0.000 description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 21
- 239000002775 capsule Substances 0.000 description 21
- 238000010276 construction Methods 0.000 description 16
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 15
- 239000012876 carrier material Substances 0.000 description 15
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 229960004436 budesonide Drugs 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 210000002345 respiratory system Anatomy 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000011164 primary particle Substances 0.000 description 6
- 108010078777 Colistin Proteins 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 235000019592 roughness Nutrition 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960001127 colistin sulfate Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 4
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 4
- 238000010408 sweeping Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000011362 coarse particle Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000003746 surface roughness Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000032953 Device battery issue Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241001126918 Sycon Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940107791 foradil Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000011044 inertial separation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940072266 pulmicort Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940090585 serevent Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129703A DE10129703A1 (de) | 2001-06-22 | 2001-06-22 | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| PCT/EP2002/006610 WO2003000325A1 (en) | 2001-06-22 | 2002-06-15 | Powder formulation disintegrating system and method for dry powder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20035654D0 NO20035654D0 (no) | 2003-12-17 |
| NO20035654L NO20035654L (no) | 2004-02-18 |
| NO332992B1 true NO332992B1 (no) | 2013-02-11 |
Family
ID=7688810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20035654A NO332992B1 (no) | 2001-06-22 | 2003-12-17 | Disintegreringsmidler for torrpulverinhalatorer og inhalator |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1397174B1 (cs) |
| JP (1) | JP4116537B2 (cs) |
| KR (1) | KR100904955B1 (cs) |
| CN (1) | CN100337699C (cs) |
| AR (1) | AR034616A1 (cs) |
| AT (1) | ATE477826T1 (cs) |
| AU (1) | AU2009200071B2 (cs) |
| BG (1) | BG66589B1 (cs) |
| BR (2) | BRPI0210026B8 (cs) |
| CA (1) | CA2445892C (cs) |
| CY (1) | CY1110924T1 (cs) |
| CZ (1) | CZ302528B6 (cs) |
| DE (2) | DE10129703A1 (cs) |
| DK (1) | DK1397174T3 (cs) |
| ES (1) | ES2350973T3 (cs) |
| HR (1) | HRP20040058B1 (cs) |
| HU (1) | HU227457B1 (cs) |
| IL (3) | IL158614A0 (cs) |
| MX (1) | MXPA03011550A (cs) |
| NO (1) | NO332992B1 (cs) |
| NZ (1) | NZ530308A (cs) |
| PL (1) | PL204900B1 (cs) |
| PT (1) | PT1397174E (cs) |
| RU (1) | RU2291717C2 (cs) |
| SI (1) | SI1397174T1 (cs) |
| SK (1) | SK288034B6 (cs) |
| TW (1) | TW567075B (cs) |
| UA (1) | UA74648C2 (cs) |
| WO (1) | WO2003000325A1 (cs) |
| ZA (1) | ZA200308555B (cs) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP1488819A1 (en) | 2003-06-16 | 2004-12-22 | Rijksuniversiteit te Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
| RU2258539C1 (ru) * | 2004-03-23 | 2005-08-20 | Чучалин Александр Григорьевич | Порошковый ингалятор |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| DE102005046645B3 (de) * | 2005-09-29 | 2006-07-20 | Braunform Gmbh | Pulverinhalator |
| DE102005046644B3 (de) * | 2005-09-29 | 2006-07-20 | Braunform Gmbh | Pulverinhalator |
| DE102006007495A1 (de) | 2006-02-17 | 2007-08-23 | Siegfried Generics International Ag | Dispergiereinheit |
| JP2009533104A (ja) * | 2006-04-13 | 2009-09-17 | ベーリンガー インゲルハイム マイクロパーツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 計量投与器具 |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| EP2011538B1 (en) * | 2007-07-06 | 2016-02-17 | Vectura Delivery Devices Limited | Inhaler |
| EP2020249A1 (de) | 2007-08-01 | 2009-02-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Inhalator |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| DE102007041720A1 (de) * | 2007-09-04 | 2009-03-05 | Alfred Von Schuckmann | Vorrichtung zur Darreichung eines blisterverpackten Medikaments |
| US8439033B2 (en) * | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
| EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
| EP2082764A1 (en) * | 2008-01-24 | 2009-07-29 | Boehringer Ingelheim International GmbH | Inhaler |
| EP2082769B1 (en) | 2008-01-24 | 2015-06-03 | Vectura Delivery Devices Limited | Inhaler |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| NZ588881A (en) * | 2008-05-23 | 2012-04-27 | Otsuka Pharma Co Ltd | Inhaler for dispensing a medicament powder |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
| EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
| EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
| EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
| WO2010102148A2 (en) * | 2009-03-04 | 2010-09-10 | Mannkind Corporation | An improved dry powder drug delivery system |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| JP6247439B2 (ja) * | 2009-11-13 | 2017-12-13 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 薬物製品、乾燥粉末吸入器、および、ポリフラックスコライダ配置体 |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| US8974450B2 (en) | 2011-02-03 | 2015-03-10 | Covidien Lp | System and method for ablation procedure monitoring using electrodes |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
| EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
| EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| CA2846899C (en) | 2011-09-07 | 2019-12-03 | Syphase, Llc | Dry powder inhalation device |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2617448A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhalation device for powdered drugs |
| EP2617450A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhaltion device for powdered drugs |
| EP2617449A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhalation device for powdered drugs |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
| EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| PT2931275T (pt) | 2012-12-17 | 2022-06-30 | Almirall Sa | Aclidínio para usar no aumento da atividade física na vida diária de um doente que sofre de doença pulmonar obstrutiva crónica |
| US9518050B2 (en) | 2012-12-18 | 2016-12-13 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity |
| AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| WO2015091285A1 (en) | 2013-12-19 | 2015-06-25 | Almirall S.A. | Dosage formulation comprising salmeterol and fluticasone propionate |
| EP2944343A1 (en) | 2014-05-15 | 2015-11-18 | AstraZeneca AB | Dry powder inhaler |
| HRP20180735T1 (hr) * | 2014-06-06 | 2018-06-29 | Rijksuniversiteit Groningen | Inhalator za suhi prah aktiviran udisanjem |
| US10765818B2 (en) | 2014-11-26 | 2020-09-08 | Vectura Delivery Devices Limited | Dry powder inhaler |
| CA3206868A1 (en) | 2015-01-14 | 2016-07-21 | Respira Therapeutics, Inc. | Powder dispersion methods and devices |
| EP3286178A1 (en) | 2015-04-21 | 2018-02-28 | Almirall S.A. | Amino-substituted heterocyclic derivatives as sodium channel inhibitors |
| WO2016202800A1 (en) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2017076990A1 (en) | 2015-11-05 | 2017-05-11 | Almirall, S.A. | Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide |
| RU2634258C1 (ru) * | 2016-11-08 | 2017-10-24 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Наполнитель для капсульного ингалятора |
| WO2018100462A1 (en) * | 2016-11-30 | 2018-06-07 | Philip Morris Products S.A. | Inhaler with sized cavity |
| EP3600504B1 (en) | 2017-03-28 | 2023-07-12 | Concentrx Pharmaceuticals, Inc. | Device for delivering dry powder medicaments |
| CN107123354B (zh) * | 2017-05-21 | 2019-03-19 | 谭淞文 | 分选花形微粒载体的吸入器、呼吸道及肺部模型设备集成 |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| US20210113787A1 (en) * | 2018-02-19 | 2021-04-22 | Philip Morris Products S.A. | Dry powder inhaler |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110201279B (zh) * | 2018-02-28 | 2021-05-11 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN111514418B (zh) * | 2019-06-12 | 2022-01-14 | 中南大学湘雅二医院 | 一种自吸式经鼻粉末材料给送装置 |
| CN111359060A (zh) * | 2020-02-20 | 2020-07-03 | 深圳麦克韦尔科技有限公司 | 雾化吸嘴及雾化装置 |
| US12117379B2 (en) * | 2020-05-15 | 2024-10-15 | Horiba, Ltd. | Sample dispersing device and sample dispersing method |
| CN112030136B (zh) * | 2020-09-01 | 2024-12-27 | 江苏微导纳米科技股份有限公司 | 镀膜腔体及粉末镀膜装置 |
| CN113750331B (zh) * | 2021-08-18 | 2022-08-16 | 华中科技大学 | 一种干粉吸入器 |
| CN114632235B (zh) * | 2022-03-04 | 2023-04-25 | 华中科技大学 | 一种干粉吸入器 |
| CN115006656A (zh) * | 2022-05-18 | 2022-09-06 | 苏州易合医药有限公司 | 一种可连续提供肺部活性剂粉雾剂的给药装置 |
| CN117547693B (zh) * | 2023-12-20 | 2025-08-01 | 上海新黄河制药有限公司 | 一种适用于双储库粉雾剂装置的流道 |
| CN118575973B (zh) * | 2024-06-27 | 2025-11-21 | 黑龙江飞鹤乳业有限公司 | 压缩食品粉末的制备方法及制备压缩食品的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1478138A (en) * | 1973-07-18 | 1977-06-29 | Beecham Group Ltd | Device for the administration of powders |
| IT7920688U1 (it) | 1979-02-05 | 1980-08-05 | Chiesi Paolo | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| NZ238489A (en) * | 1990-06-14 | 1995-09-26 | Rhone Poulenc Rorer Ltd | Inhaler with capsule in swirling chamber: capsule pierced in chamber |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| DE4211475A1 (de) * | 1991-12-14 | 1993-06-17 | Asta Medica Ag | Pulverinhalator |
| DE4239402A1 (de) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| US5829434A (en) | 1992-12-18 | 1998-11-03 | Schering Corporation | Inhaler for powdered medications |
| HU220212B (hu) * | 1994-10-04 | 2001-11-28 | The Procter & Gamble Company | Berendezések és eljárások szemcsés anyagok elektrosztatikus permetezésére |
| DE19522416C2 (de) * | 1995-06-21 | 2003-11-20 | Sofotec Gmbh & Co Kg | Vorrichtung zum Dispergieren von Pulver in einem Luftstrom zur Verwendung mit Pulver-Inhalatoren |
| BR9608997A (pt) * | 1995-06-21 | 1999-06-29 | Asta Medica Ag | Cartucho para pó farmacêutico com dispositivo de medição integrado e intalador para medicamentos em pó |
| FR2738153B1 (fr) * | 1995-09-04 | 1998-01-02 | Valois | Appareil d'inhalation destine a distribuer des doses precises et reproductibles de produit pulverulent |
| EP1129705A1 (en) * | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
-
2001
- 2001-06-22 DE DE10129703A patent/DE10129703A1/de not_active Withdrawn
-
2002
- 2002-06-12 TW TW091112804A patent/TW567075B/zh not_active IP Right Cessation
- 2002-06-15 EP EP02780833A patent/EP1397174B1/en not_active Expired - Lifetime
- 2002-06-15 BR BRPI0210026A patent/BRPI0210026B8/pt not_active IP Right Cessation
- 2002-06-15 PT PT02780833T patent/PT1397174E/pt unknown
- 2002-06-15 DK DK02780833.6T patent/DK1397174T3/da active
- 2002-06-15 DE DE60237366T patent/DE60237366D1/de not_active Expired - Lifetime
- 2002-06-15 HR HRP20040058AA patent/HRP20040058B1/hr not_active IP Right Cessation
- 2002-06-15 HU HU0400212A patent/HU227457B1/hu unknown
- 2002-06-15 RU RU2004102037/14A patent/RU2291717C2/ru active
- 2002-06-15 JP JP2003506966A patent/JP4116537B2/ja not_active Expired - Lifetime
- 2002-06-15 CZ CZ20040046A patent/CZ302528B6/cs not_active IP Right Cessation
- 2002-06-15 PL PL365946A patent/PL204900B1/pl unknown
- 2002-06-15 MX MXPA03011550A patent/MXPA03011550A/es active IP Right Grant
- 2002-06-15 CA CA2445892A patent/CA2445892C/en not_active Expired - Lifetime
- 2002-06-15 SK SK27-2004A patent/SK288034B6/sk unknown
- 2002-06-15 KR KR1020037016628A patent/KR100904955B1/ko not_active Expired - Lifetime
- 2002-06-15 ES ES02780833T patent/ES2350973T3/es not_active Expired - Lifetime
- 2002-06-15 SI SI200230925T patent/SI1397174T1/sl unknown
- 2002-06-15 BR BR0210026-6A patent/BR0210026A/pt active IP Right Grant
- 2002-06-15 NZ NZ530308A patent/NZ530308A/en not_active IP Right Cessation
- 2002-06-15 AT AT02780833T patent/ATE477826T1/de active
- 2002-06-15 CN CNB02812121XA patent/CN100337699C/zh not_active Expired - Lifetime
- 2002-06-15 WO PCT/EP2002/006610 patent/WO2003000325A1/en not_active Ceased
- 2002-06-15 UA UA20031211618A patent/UA74648C2/uk unknown
- 2002-06-15 IL IL15861402A patent/IL158614A0/xx unknown
- 2002-06-21 AR ARP020102359A patent/AR034616A1/es active IP Right Grant
-
2003
- 2003-10-27 IL IL158614A patent/IL158614A/en active IP Right Grant
- 2003-11-03 ZA ZA200308555A patent/ZA200308555B/en unknown
- 2003-12-17 NO NO20035654A patent/NO332992B1/no not_active IP Right Cessation
-
2004
- 2004-01-06 BG BG108512A patent/BG66589B1/bg unknown
-
2009
- 2009-01-08 AU AU2009200071A patent/AU2009200071B2/en not_active Expired
-
2010
- 2010-11-17 CY CY20101101039T patent/CY1110924T1/el unknown
-
2011
- 2011-02-01 IL IL210983A patent/IL210983A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332992B1 (no) | Disintegreringsmidler for torrpulverinhalatorer og inhalator | |
| US6681768B2 (en) | Powder formulation disintegrating system and method for dry powder inhalers | |
| US7344734B2 (en) | Powder formulation | |
| JP5705112B2 (ja) | ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤 | |
| De Boer et al. | Air classifier technology (ACT) in dry powder inhalation: Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler | |
| De Boer et al. | Air classifier technology (ACT) in dry powder inhalation: part 3. Design and development of an air classifier family for the Novolizer® multi-dose dry powder inhaler | |
| KR102452773B1 (ko) | 흡입용 의약 조성물 | |
| AU2002350483A1 (en) | Powder formulation disintegrating system and method for dry powder | |
| HK1064313B (en) | Powder formulation disintegrating system and dry powder inhalers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ASTRAZENECA AB, SE |
|
| MM1K | Lapsed by not paying the annual fees |